	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	7,083	9,641	11,287	12,770	14,256	17,494	15,804	14,665	15,375	15,163	16,405	16,642	20,011	22,708	27,958
Cost of Operating Revenue	3,023	4,119	4,357	4,956	5,296	6,515	6,834	6,230	6,920	6,793	8,305	8,544	8,631	8,999	8,702
Gross Profit	4,060	5,522	6,929	7,814	8,959	10,979	8,970	8,435	8,455	8,370	8,101	8,097	11,380	13,709	19,256
Gross Margin	57.3	57.3	61.4	61.2	62.8	62.8	56.8	57.5	55.0	55.2	49.4	48.7	56.9	60.4	68.9
Total Operating Expenses	5,826	7,639	8,442	9,457	11,017	13,895	13,739	12,940	13,963	13,472	15,081	15,721	17,202	18,491	21,174
Operating Profit	1,257	2,002	2,845	3,313	3,238	3,599	2,065	1,725	1,412	1,691	1,325	921	2,809	4,217	6,784
Operating Margin	17.8	20.8	25.2	25.9	22.7	20.6	13.1	11.8	9.2	11.2	8.1	5.5	14.0	18.6	24.3
Financing Income/(Expense) - Net	-48	-39	34	89	51	-86	-103	-21	53	-88	-54	-194	-230	-138	222
Profit before Taxes	1,196	1,925	2,832	3,415	3,329	3,543	547	1,409	757	1,676	-1,372	716	2,422	4,015	6,873
Income Taxes	309	584	962	970	1,059	979	288	888	1,157	449	137	269	487	709	1,517
Profit after Tax	868	1,314	1,836	2,403	2,261	2,557	251	607	-269	1,217	-1,528	430	1,914	3,282	5,333
PAT Margin	12.2	13.6	16.3	18.8	15.9	14.6	1.6	4.1	-1.8	8.0	-9.3	2.6	9.6	14.5	19.1
EPS - Basic - ex Extraordinary Items	19.43	29.39	40.99	53.54	50.23	56.69	5.56	11.32	-8.82	26.84	-33.65	9.46	42.05	71.95	116.75
EPS - Diluted - ex Extraordinary Items	19.36	29.26	40.79	53.20	49.93	56.46	5.54	11.47	-8.82	26.97	-33.65	9.41	41.87	71.69	116.44
EBIT	1,257	2,002	2,845	3,313	3,238	3,599	2,065	1,725	1,412	1,691	1,325	921	2,809	4,217	6,784
EBITDA	1,485	2,334	3,139	3,748	3,725	4,511	3,151	2,571	2,382	2,578	2,143	1,762	3,805	5,305	8,160
EBITDA Margin	21.0	24.2	27.8	29.3	26.1	25.8	19.9	17.5	15.5	17.0	13.1	10.6	19.0	23.4	29.2

Balance Sheet

Abridged

Understanding Balance Sheet

Lupin Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	4,342	5,143	6,100	7,804	9,887	11,953	12,210	13,854	15,413	13,986	12,458	12,451	13,448	16,799	24,027
Long-Term Investments	-	-	-	3	6	6	6	160	6	46	125	47	201	70	1,515
Property Plant & Equipment - Net	2,449	2,663	2,888	3,147	4,330	5,351	5,864	5,930	5,124	5,234	5,397	5,540	5,494	5,504	6,144
Total Non-Current Assets	3,640	3,771	4,106	5,457	12,737	14,654	14,096	14,096	9,571	9,624	9,364	10,505	10,550	12,406	14,337
Total Assets	7,982	8,914	10,206	13,261	22,625	26,607	26,305	27,949	24,984	23,610	21,821	22,956	23,997	29,205	38,365
Total Current Liabilities	3,120	3,007	2,630	3,463	5,061	6,121	5,096	6,130	9,225	8,436	8,276	9,265	8,502	8,961	12,651
Long Term Debt	433	247	151	102	5,374	5,648	6,425	6,642	2,016	275	364	214	155	2,031	2,138
Total Non-Current Liabilities	777	643	578	600	6,368	6,955	7,593	8,030	3,177	1,316	1,323	1,148	1,122	2,949	3,200
Total Liabilities	3,897	3,650	3,208	4,064	11,429	13,075	12,688	14,160	12,403	9,752	9,599	10,413	9,624	11,911	15,851
Total Shareholders' Equity	4,013	5,204	6,932	9,173	11,163	13,498	13,577	13,742	12,537	13,803	12,153	12,465	14,290	17,204	22,448
Minority Interest	72	59	67	24	32	35	40	47	44	55	69	78	83	91	65
Total Equity	4,085	5,264	6,999	9,197	11,195	13,532	13,617	13,789	12,581	13,858	12,222	12,543	14,373	17,294	22,513
Total Liabilities & Equity	7,982	8,914	10,206	13,261	22,625	26,607	26,305	27,949	24,984	23,610	21,821	22,956	23,997	29,205	38,365

Cash Flow

Abridged

Understanding Cash Flow Statement

Lupin Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1,111	1,770	2,459	2,890	2,732	3,518	2,607	1,990	1,727	1,922	291	1,376	3,326	4,285	6,518
Working Capital - Increase/(Decrease)	-581	-549	-466	-95	-3,126	505	-1,019	-500	-471	-192	-15	327	86	-1,411	634
Net CF from Operating Activities	530	1,220	1,993	2,795	-394	4,023	1,588	1,490	1,256	1,730	276	1,703	3,412	2,875	7,152
Capital Expenditures - Net	505	541	525	868	5,781	2,601	1,490	960	671	671	898	1,461	917	1,653	1,807
Net CF from Investing Activities	-749	-534	-875	-1,127	-7,008	-2,587	429	-3,387	963	-1,279	1,259	-1,319	-1,758	-4,302	-4,081
Dividends Paid - Cash - Total	142	143	321	134	337	338	338	225	226	272	295	183	183	365	548
Stock - Issuance/(Retirement) - Net	0	0	0	0	33	0	0	0	0	0	0	0	0	40	-51
Debt - LT & ST - Issuance/(Retirement) - Total	307	-465	-530	-70	6,208	948	-895	1,292	-267	-1,492	-1,169	70	-1,733	2,312	153
Net Cash Flow from Financing Activities	147	-621	-829	-186	5,895	584	-1,288	1,025	-534	-1,753	-1,448	-111	-1,901	1,987	-446
Free Cash Flow to Equity	332	215	938	1,857	32	2,370	-797	1,822	318	-434	-1,791	312	762	3,534	5,497
Free Operating CF net dividend	-121	526	1,142	1,789	-6,553	1,048	-304	280	357	780	-924	21	2,300	827	4,549
Free Operating CF	21	669	1,464	1,924	-6,216	1,386	35	504	583	1,052	-629	203	2,483	1,192	5,097

Business Segment Analysis

FY End:

Mar 25

Lupin Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharmaceuticals (99.5%)₹ 22,604.31 Crothers (0.5%)₹ 105.45 Cr

Assets

Pharmaceuticals (99.1%)₹ 29,282.61 Crothers (0.9%)₹ 274.92 Cr

Regional Segment Analysis

FY End:

Mar 25

Lupin Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (37.5%)₹ 8,504.64 CrUnited States (34.0%)₹ 7,723.90 CrOthers (28.5%)₹ 6,479.36 Cr

Historical Segment Analysis

Track how Lupin Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31

Pharmaceuticals	673	678	905	1,500

Frequently Asked Questions

What is the revenue of Lupin Ltd.?

The latest trailing twelve month revenue of Lupin Ltd. is ₹ 27,958.00 Cr, reflecting a 1-year growth of 23.12% and a 3-year CAGR of 18.88%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Lupin Ltd.?

The latest trailing twelve month net profit (PAT) of Lupin Ltd. is ₹ 5,332.84 Cr, with a 3-year earnings CAGR of 131.28%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Lupin Ltd.?

The trailing twelve month EBITDA of Lupin Ltd. is approximately ₹ 6,784.04 Cr (based on an operating margin of 24.27%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Lupin Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Lupin Ltd. is 116.44. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Lupin Ltd.?

The debt-to-equity ratio of Lupin Ltd. stands at 0.29. The interest coverage ratio is 15.61x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Lupin Ltd.?

The estimated book value per share of Lupin Ltd. is 506.59 (derived from a P/B ratio of 4.89 and market price of ₹ 2,476.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Lupin Ltd.?

The trailing twelve month operating cash flow of Lupin Ltd. is ₹ 7,151.74 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Lupin Ltd. report consolidated or standalone financials?

Lupin Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.